FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2258178785> ?p ?o ?g. }

• W2258178785 endingPage "1416" @default.
• W2258178785 startingPage "1411" @default.
• W2258178785 abstract "Fifty patients with recurrent Hodgkin's disease have been treated with high-dose therapy followed by autologous bone marrow transplantation. Forty-one patients had extranodal sites of relapse and 31 patients had constitutional symptoms. Two patients had been treated with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP), lomustine, vinblastine, procarbazine, and prednisone (CcVPP), and radiation; 16 patients with MOPP, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), radiation, and lomustine, etoposide, and prednisone (CEP); 20 patients with alternating MOPP/ABVD, and 12 patients with alternating MOPP/ABVD followed by CEP and radiation. Eighteen patients had progressive disease during alternating MOPP/ABVD protocol alone or during conventional salvage therapy; 32 patients had had a complete remission with first-line therapy but later relapsed, 25 of them having received conventional salvage therapy; 12 achieved no response or progression (resistant-relapse patients); and 13 responded partially or completely (sensitive-relapse patients). Complete remission occurred in 24 patients (48%) with a median duration of 24 months and 16 patients (32%) achieved partial response with a median duration of 9 months, for an overall response rate of 80%. Ten patients failed to respond and died in progressive disease 1 to 10 months (median, 6 months) after transplantation. Toxicity was significant including infections (20%), liver enzymes and alkaline phosphatase elevations (100%), and carmustine lung toxicity (7%). There were two treatment-related deaths; one patient died of Pseudomonas aeruginosa septicemia and another patient died of cerebral hemorrhage. These results validate the procedure of high-dose therapy followed by autologous bone marrow transplantation in inducing remission in these advanced, highly-treated patients. Clearly, the question of whether high-dose therapy and transplantation will eventually supersede new conventional salvage therapies will be addressed after controlled clinical studies." @default.
• W2258178785 created "2016-06-24" @default.
• W2258178785 creator A5003272531 @default.
• W2258178785 creator A5004493684 @default.
• W2258178785 creator A5008400371 @default.
• W2258178785 creator A5016794322 @default.
• W2258178785 creator A5024587881 @default.
• W2258178785 creator A5028913158 @default.
• W2258178785 creator A5031937532 @default.
• W2258178785 creator A5051200932 @default.
• W2258178785 creator A5070417705 @default.
• W2258178785 creator A5081368450 @default.
• W2258178785 date "1988-09-01" @default.
• W2258178785 modified "2023-10-16" @default.
• W2258178785 title "High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report." @default.
• W2258178785 cites W124574976 @default.
• W2258178785 cites W1502285746 @default.
• W2258178785 cites W1545719768 @default.
• W2258178785 cites W1808994586 @default.
• W2258178785 cites W1842869534 @default.
• W2258178785 cites W1979300931 @default.
• W2258178785 cites W2022776680 @default.
• W2258178785 cites W2071060238 @default.
• W2258178785 cites W2102785744 @default.
• W2258178785 cites W2185768010 @default.
• W2258178785 cites W2269861991 @default.
• W2258178785 cites W2301707085 @default.
• W2258178785 cites W2313423582 @default.
• W2258178785 cites W2328232339 @default.
• W2258178785 cites W2339709756 @default.
• W2258178785 cites W2403834487 @default.
• W2258178785 cites W2419245523 @default.
• W2258178785 cites W2428921896 @default.
• W2258178785 cites W2431457530 @default.
• W2258178785 doi "https://doi.org/10.1200/jco.1988.6.9.1411" @default.
• W2258178785 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2458439" @default.
• W2258178785 hasPublicationYear "1988" @default.
• W2258178785 type Work @default.
• W2258178785 sameAs 2258178785 @default.
• W2258178785 citedByCount "154" @default.
• W2258178785 countsByYear W22581787852012 @default.
• W2258178785 countsByYear W22581787852013 @default.
• W2258178785 countsByYear W22581787852015 @default.
• W2258178785 countsByYear W22581787852017 @default.
• W2258178785 countsByYear W22581787852019 @default.
• W2258178785 countsByYear W22581787852020 @default.
• W2258178785 crossrefType "journal-article" @default.
• W2258178785 hasAuthorship W2258178785A5003272531 @default.
• W2258178785 hasAuthorship W2258178785A5004493684 @default.
• W2258178785 hasAuthorship W2258178785A5008400371 @default.
• W2258178785 hasAuthorship W2258178785A5016794322 @default.
• W2258178785 hasAuthorship W2258178785A5024587881 @default.
• W2258178785 hasAuthorship W2258178785A5028913158 @default.
• W2258178785 hasAuthorship W2258178785A5031937532 @default.
• W2258178785 hasAuthorship W2258178785A5051200932 @default.
• W2258178785 hasAuthorship W2258178785A5070417705 @default.
• W2258178785 hasAuthorship W2258178785A5081368450 @default.
• W2258178785 hasConcept C126322002 @default.
• W2258178785 hasConcept C141071460 @default.
• W2258178785 hasConcept C2776305933 @default.
• W2258178785 hasConcept C2776694085 @default.
• W2258178785 hasConcept C2776755627 @default.
• W2258178785 hasConcept C2777132456 @default.
• W2258178785 hasConcept C2778119113 @default.
• W2258178785 hasConcept C2778720950 @default.
• W2258178785 hasConcept C2778822529 @default.
• W2258178785 hasConcept C2779112685 @default.
• W2258178785 hasConcept C2779429289 @default.
• W2258178785 hasConcept C2779434656 @default.
• W2258178785 hasConcept C2780147359 @default.
• W2258178785 hasConcept C2780775027 @default.
• W2258178785 hasConcept C2780964509 @default.
• W2258178785 hasConcept C2911091166 @default.
• W2258178785 hasConcept C71924100 @default.
• W2258178785 hasConcept C90924648 @default.
• W2258178785 hasConceptScore W2258178785C126322002 @default.
• W2258178785 hasConceptScore W2258178785C141071460 @default.
• W2258178785 hasConceptScore W2258178785C2776305933 @default.
• W2258178785 hasConceptScore W2258178785C2776694085 @default.
• W2258178785 hasConceptScore W2258178785C2776755627 @default.
• W2258178785 hasConceptScore W2258178785C2777132456 @default.
• W2258178785 hasConceptScore W2258178785C2778119113 @default.
• W2258178785 hasConceptScore W2258178785C2778720950 @default.
• W2258178785 hasConceptScore W2258178785C2778822529 @default.
• W2258178785 hasConceptScore W2258178785C2779112685 @default.
• W2258178785 hasConceptScore W2258178785C2779429289 @default.
• W2258178785 hasConceptScore W2258178785C2779434656 @default.
• W2258178785 hasConceptScore W2258178785C2780147359 @default.
• W2258178785 hasConceptScore W2258178785C2780775027 @default.
• W2258178785 hasConceptScore W2258178785C2780964509 @default.
• W2258178785 hasConceptScore W2258178785C2911091166 @default.
• W2258178785 hasConceptScore W2258178785C71924100 @default.
• W2258178785 hasConceptScore W2258178785C90924648 @default.
• W2258178785 hasIssue "9" @default.
• W2258178785 hasLocation W22581787851 @default.
• W2258178785 hasLocation W22581787852 @default.
• W2258178785 hasOpenAccess W2258178785 @default.
• W2258178785 hasPrimaryLocation W22581787851 @default.

• next